VRAX vs REVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REVB Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Revelation Biosciences, Inc. Common Stock (REVB) driven by superior Valuation, Momentum & Technical while VRAX counters with relative strength in Growth & Margin. Fundamentally, VRAX trades at N/M Forward P/E with -51515.2% operating margin (+684.9% YoY revenue) versus REVB at 0.9x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VRAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against REVB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VRAX | REVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $823,939 | $2.4M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | 0.9x | Lower Multiple | REVB |
| Forward P/E Ratio Valuation | N/M | 0.9x | Lower Multiple | REVB |
| Revenue Growth (YoY) Growth | +684.9% | +0.0% | Higher Growth | VRAX |
| Operating Margin (TTM) Profitability | -51515.2% | 0.0% | Higher Margin | REVB |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -78.6% | -133.4% | Higher ROE | VRAX |
| 52-Week Range Position Momentum | 3% ($0โ$13) | 80% ($0โ$5) | Stronger Trend | REVB |
| Beta / 30D Volatility Risk Regime | -9.35ฮฒ ยท 161% Vol | 2.95ฮฒ ยท 2364% Vol | Lower Realized Risk | VRAX |
| Unified Institutional Score Composite Signal | 41.7 / 100 (SELL) | 34.4 / 100 (SELL) | Higher Composite | VRAX |